

AD \_\_\_\_\_

GRANT NUMBER DAMD17-96-1-6054

TITLE: Anti-Breast Cancer Effects of Vitamin D3 Analogs Either Alone or in Combination With Other Agents

PRINCIPAL INVESTIGATOR: Phillip H. Koeffler, M.D.

CONTRACTING ORGANIZATION: Cedars-Sinai Medical Center  
Los Angeles, California 90048

REPORT DATE: October 1997

TYPE OF REPORT: Annual

PREPARED FOR: Commander  
U.S. Army Medical Research and Materiel Command  
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;  
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTED 2

19980310 062

# REPORT DOCUMENTATION PAGE

*Form Approved*  
**OMB No. 0704-0188**

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

<b>1. AGENCY USE ONLY (Leave blank)</b>		<b>2. REPORT DATE</b> October 1997	<b>3. REPORT TYPE AND DATES COVERED</b> Annual (1 Oct 96 - 30 Sep 97)	
<b>4. TITLE AND SUBTITLE</b> Anti-Breast Cancer Effects of Vitamin D3 Analogs Either Alone or in Combination With Other Agents			<b>5. FUNDING NUMBERS</b> DAMD17-96-1-6054	
<b>6. AUTHOR(S)</b> Phillip H. Koeffler, M.D.				
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> Cedars-Sinai Medical Center Los Angeles, California 90048			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> Commander U.S. Army Medical Research and Materiel Command Fort Detrick, Frederick, Maryland 21702-5012			<b>10. SPONSORING/MONITORING AGENCY REPORT NUMBER</b>	
<b>11. SUPPLEMENTARY NOTES</b>				
<b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for public release; distribution unlimited			<b>12b. DISTRIBUTION CODE</b>	
<b>13. ABSTRACT (Maximum 200)</b>  We have studied the effect of vitamin D analogs on growth of various breast cancer cell lines in vitro as well as in vivo and have identified the 19-nor-hexafluoride analogs as being particularly potent in their activity. Furthermore, we have found that vitamin D <sub>3</sub> analogs can synergize with Taxol in inhibiting breast cancer. We have recently found that trogliterazone, a synthetic ligand of the peroxisome proliferator/activated receptor $\gamma$ (PPAR $\gamma$ ) can inhibit the growth of breast cancer cells and this PPAR $\gamma$ ligand with All-trans-retinoic acid can induce apoptosis of breast cancer cells. Furthermore, we have looked for genetic alterations of breast cancer including identification of alterations of the cyclin-dependent-kinase inhibitor genes including p27 <sup>KIP1</sup> and the p16 <sup>INK4A</sup> genes.				
<b>14. SUBJECT TERMS</b> Breast Cancer			<b>15. NUMBER OF PAGES</b> 11	
			<b>16. PRICE CODE</b>	
<b>17. SECURITY CLASSIFICATION OF REPORT</b> Unclassified	<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> Unclassified	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> Unclassified	<b>20. LIMITATION OF ABSTRACT</b> Unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

\_\_\_ Where copyrighted material is quoted, permission has been obtained to use such material.

\_\_\_ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

\_\_\_ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

✓ \_\_\_ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

✓ \_\_\_ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.


\_\_\_ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

\_\_\_ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

\_\_\_ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

PI - Signature

Date

 11/5/97

## TABLE OF CONTENTS

Accession Document	Page 1
Abstract	Page 2
Foreword	Page 3
Table of Contents	Page 4
Introduction	Page 5
Vitamin D <sub>3</sub> and Breast Cancer	Page 5-8
Retinoids, ligands for PPAR $\gamma$ and breast cancer	Page 9
Molecular biology of breast cancer	Page 9
Conclusion	Page 11
References	Page 11

## INTRODUCTION

The following provides descriptions of our vitamin D<sub>3</sub>, retinoid, troglitazone studies as well as our molecular biology studies in breast cancer.

### I. Vitamin D<sub>3</sub> and Breast Cancer

#### I.1) 19-nor-Hexafluoride Analogue of Vitamin D<sub>3</sub>: A novel class of potent inhibitors of proliferation of human breast cell lines

Authors: Koike M, Elstner E, Campbell M, Asou H, Uskokovic M, Tsuruoka N, and Koeffler HP

Breast cancer cells express vitamin D<sub>3</sub> receptors and 1,25-dihydroxyvitamin D<sub>3</sub> suppressed growth of these cells. We have synthesized six novel vitamin D<sub>3</sub> analogues to identify those with expanded capacity to inhibit the proliferative ability of breast cancer cells. These analogues incorporated many of the structural motifs shown previously to have antiproliferative activities, and LH [1,25-(OH)<sub>2</sub>-16-ene-23-yne-26,27-F<sub>6</sub>-19-nor D<sub>3</sub>] was the most potent analogue, suppressing at 10<sup>-11</sup>M greater than 50% clonal proliferation (ED<sub>50</sub>) of the MCF-7 and SK-BR-3 breast cancer cells, increasing the proportion of MCF-7 cells in the G<sub>0</sub>-G<sub>1</sub> phase, and decreasing those in the S phase of the cell cycle. Pulse-exposure studies showed that a 3-day-exposure to LH (10<sup>-7</sup>M) in liquid culture was adequate to achieve a 50% inhibition of MCF-7 clonal growth in soft agar in the absence of the analogue, suggesting that the growth inhibition mediated by LH is irreversible. The cyclin-dependent kinase inhibitor known as p27<sup>KIP1</sup> helps regulate the cell cycle and can mediate growth arrest in response to extracellular growth inhibitors. The analogue LH (10<sup>-7</sup>M) induced elevated expression of p27<sup>KIP1</sup> in MCF-7 and SK-BR-3 cells. Taken together, these results indicate that LH is an extremely potent vitamin D<sub>3</sub> analogue markedly inhibiting clonal growth of MCF-7 and SK-BR-3 cells. Taken together, these results indicate that LH is an extremely potential vitamin D<sub>3</sub> analogue markedly inhibiting clonal growth of MCF-7 and SK-BR-3 cells with concomitant cell cycle arrest at G<sub>0</sub>-G<sub>1</sub> and increased expression of p27<sup>KIP1</sup>. Compound LH is worthy of in vivo analysis for possible future clinical trials.

**Submitted for publication, 1997.**

#### I.2) Combined effect of vitamin D<sub>3</sub> analogs and Paclitaxel on the growth of the MCF-7 breast cancer cells in vivo

Authors: Koshizuka K, Koike M, Asou H, Cho S, Stephen T, Rude R, Binderup L, Uskokovic M, and Koeffler HP

Vitamin D<sub>3</sub> analogs and paclitaxel (Taxol) are able to inhibit growth of a variety of malignant cells. We examined the ability of three vitamin D<sub>3</sub> compounds to inhibit growth of a human mammary cancer (MCF-7) in BNX triple immunodeficient mice either alone or with Taxol. Vitamin D<sub>3</sub> analogs were 1,25(OH)<sub>2</sub>D<sub>3</sub> (code name, Compound C), 1,25(OH)<sub>2</sub>-16-ene-23-yne-nor-26,27-F<sub>6</sub>-D<sub>3</sub> (Compound LH) and 24a,

26a, 27a,-trihomo-22,24-diene-1,25(OH)<sub>2</sub>D<sub>3</sub> (EB1089). At the doses chosen, the antitumor effect of vitamin D<sub>3</sub> analogs alone was greater than that of Taxol alone, and an additive effect was observed when vitamin D<sub>3</sub> analog and Taxol were administered together. EB1089 was the most potent compound; and the EB1089 plus Taxol was the most potent combination decreasing the tumor mass nearly 5-fold compared to control. Except for the Taxol group, each experimental cohort weighed ≤ 20% of the control group. None of the animals became hypercalcemic. Their complete blood counts, serum electrolyte analysis as well as their liver and renal functions were all fairly similar and within the normal range. In summary, this combination of a vitamin D<sub>3</sub> analog and Taxol has the potential to be a therapy for breast cancer.

I.3) **Effect of vitamin D<sub>3</sub> analog, paclitaxel, and cisplatin on the growth of MCF-7 human breast cancer cells in vivo**

Authors: Koshizuka K, Koike M, Kubota T, Said J, Binderup L, and Koeffler HP

Vitamin D<sub>3</sub> analogs, paclitaxel (Taxol) and cisplatin (CDDP) inhibit growth of a variety of malignant cells. We examined the ability of a novel 20-epi-vitamin D<sub>3</sub> analog (code name, CB1093), Taxol and CDDP either alone or in combination to inhibit growth of a human mammary cancer (MCF-7) growing in BNX triple immunodeficient mice. Control animals demonstrated infiltrating poorly differentiated adenocarcinomas. At the doses chosen, the antitumor effect of Taxol alone was greater than that of either CB1093 + Taxol or CB1093 + CDDP + Taxol were administered together. The combination of CB1093 + Taxol + CDDP was most potent, decreasing tumor weight by nearly 83% compared to control tumors and producing extensive necrosis of the remaining tumor mass. No additive effect on reduction of tumor weights occurred by combining either CB1093 + CDDP or Taxol + CDDP compared to Taxol alone. For all cohorts, their complete hematopoietic blood counts, serum electrolyte analyses including serum calciums as well as their liver and renal functions were within the normal range. Extensive histological analyses of the liver, spleen, kidney, bone marrow, skin and subcutaneous fat pad from these mice showed no changes from the control mice. In summary, combined therapy with a potent vitamin D<sub>3</sub> analog, Taxol, and CDDP may hold promise in the treatment of patients with breast cancer.

**Submitted for publication, 1997.**

I.4) **Potent Vitamin D<sub>3</sub> analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells, but have differing molecular effects**

Authors: Campbell MJ, Reddy G, Koeffler HP.

The seco-steroid hormone, 1 $\alpha$ , 25 dihydroxyvitamin D<sub>3</sub> (1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>) binds to a specific nuclear receptor that acts as a ligand inducible transcription factor. The resulting genomic effects include partial arrest in G<sub>0</sub>/G<sub>1</sub> of the cell cycle and induction of differentiation; these effects have been observed in various types of cancer. Recently, we produced enzymatically the natural 24-oxo metabolites of

$1\alpha,25(\text{OH})_2\text{D}_3$  and two of its potent synthetic analogs ( $1\alpha,25-(\text{OH})_2-16\text{-ene-D}_3$  and  $1\alpha,25-(\text{OH})_2-20\text{-epi-D}_3$ ) using a rat kidney perfusion system. We have found that 24-oxo metabolites of both  $1\alpha,25(\text{OH})_2\text{D}_3$  and its analogs have either the same or greater antiproliferative activity against various cancer cells as their parental compounds. Notably, two cell lines (DU-145 (prostate cancer) and MDA-MB-436 [breast cancer]) that were extremely resistant to the antiproliferative effects of vitamin  $\text{D}_3$  analogs displayed greater sensitivity towards the 24-oxo metabolite of the vitamin  $\text{D}_3$  analog. Similarly, the 24-oxo metabolites had the capacity to induce differentiation and apoptosis and to diminish the proportion of cells in S phase. Most interestingly, while the analog  $1\alpha,25-(\text{OH})_2-20\text{-epi-D}_3$  induced expression of BRCA1 in MCF-7 breast cancer cells; its 24-oxo metabolite dramatically suppressed BRCA1 expression. Thus, we have shown for the first time that the various biological activities produced by the hormone  $1\alpha,25(\text{OH})_2\text{D}_3$  and some of its analogs may represent a combination of actions by hormone  $1\alpha,25(\text{OH})_2\text{D}_3$  and its natural 24-oxo metabolites.

**J of Cell Biochem, 66(3):413-425, 1997.**

**I.5) Preadipocytes stimulate breast cancer cell growth**

Authors: Chamras H, Baggs D, Elstner E, Koeffler HP, and Heber D.

Local growth-regulatory factors elaborated by mammary stromal cells including fibroblasts, preadipocytes and adipocytes may influence breast cancer cell growth. We studied the effect of the parent Swiss 3T3 mouse fibroblast cell line and its subline 3T3-L1 preadipocytes cell line, which both were used as feeder layer, on clonal growth of human breast cancer estrogen-(ER)positive MCF-7 and ER-negative MDA-MB-231 and MDA-MB-436 cell lines. Our study showed that proliferating 3T3-L1 cells stimulated the clonal growth of MCF-7, MDA-MB-231 and MDA-MB-436 cells by two-fold, 43% and 60%, respectively. However, confluent 3T3-L1 cells lost this stimulatory ability. In contrast, the differentiated mature adipocytes significantly inhibited clonal growth of breast cancer cell lines. The identification of ligands and target receptors, involved in this process is under investigation.

**Submitted for publication, 1997.**

**I.6) The 16-ene vitamin  $\text{D}_3$  analogs**

Authors: Uskokovic M, Studzinski G, Gardner J, Reddy G, Campbell MJ, and Koeffler HP.

Numerous 16-ene vitamin D analogues were investigated as potential anticancer agents. Several structural modifications have been uncovered that contribute to the improvement in the stimulation of HL-60 cells differentiation, the inhibition of HL-60 cells proliferation and the reduction of calcemic properties *in vivo*. They include the introduction of 16-, 22E-, 23E, and 23Z-double bonds, 23-triple bond or 22R-allene, and substitution of C26 and C27-hydrogens with fluorine or methyl groups. The

biggest gains have been achieved by combination of the 16-double bond with 23-double or triple bond and 26-trifluoro or 26,27-hexafluoro substitution patterns. Separately, the combination of the 16-double bond with 22R-allene has produced a highly active analog. In respect to modifications in the ring A, the high activities in cell differentiation and inhibition of cell proliferation with significant reduction of calcemic properties were observed in the 1 $\alpha$ -fluoro, 3-desoxy, and 19-nor series. It was also shown that the lack of the 1 $\alpha$ -hydroxy group can overcome by an optimized modification in the ring D and the side chain; 25(OH)-16,23E-diene-26,27-F6D3 is fully active in HL-60 cell differentiation assay with only minimal effects on the cellular calcium homeostasis.

**Cur Pharmaceut Des, 3:99-123, 1997.**

I.7) **Towards therapeutic intervention of cancer by vitamin D compounds**

Authors: Campbell M, Koeffler HP.

We (Campbell M, Koeffler HP) reviewed the use and function of novel vitamin D analogs for treatment of human malignancy including breast cancer.

**Natl Cancer Inst, 89(3)182-186, 1997.**

I. 8) **Integrity of the 1,25-dihydroxyvitamin D<sub>3</sub> receptor in bone, lung, and other cancers**

Authors: Miller CW, Morosetti R, Campbell M, Mendoza S, and Koeffler HP.

Differentiation and proliferation can be regulated in diverse cell types by 1,25-dihydroxyvitamin D<sub>3</sub>. These effects derive from modulation of gene expression mediated by the interaction of 1,25-dihydroxyvitaminD<sub>3</sub> with the vitamin D receptor (VDR). The VDR is one of the nuclear hormone receptors. Because these transcription factors play a key role in growth control, some nuclear hormone receptors, such as retinoic acid receptor  $\alpha$ , can be disrupted in cancer. With these alterations in mind, we looked for alterations of the VDR gene in a variety of cancers, including 68 osteosarcomas, 23 other sarcomas, 34 non-small cell lung cancers, and 44 cell lines representing many tumor types. Gross integrity of the VDR gene was examined on Southern blots probed with the coding region of the VDR cDNA. The presence of point mutations targeting VDR exons 2-7 was assessed by polymerase chain reaction-single-strand conformation polymorphism analysis and direct DNA sequencing. Two alterations were detected; direct DNA sequencing of these samples revealed one silent mutation in codon 9 and a base change in intron 3. These results suggest that mutations and rearrangement of the VDR do not play a role in the cancers studied.

**Mol. Carcinog. 19:254-257, 1997.**

## II.) Retinoids, ligands for PPAR $\gamma$ and breast cancer

Authors: Elstner E, Koshizuka K, Williamson E, Hiroya A, Shintaku P, Said J, and Koeffler HP.

The peroxisome proliferator-activated receptor gamma (PPAR $\gamma$ ), a member of the nuclear hormone receptor superfamily, can be activated through its synthetic ligand, the anti-diabetic drug troglitazone (T). The retinoic acid receptor (RAR)-specific ligand, all-trans retinoic acid (ATRA) inhibits growth of breast cancer cells. Our aim was to investigate the effect of T and ATRA on proliferation, differentiation and apoptosis of breast cancer cells in vitro and in vivo. In contrast to PPAR $\gamma$ -negative human normal breast epithelial cells, fresh breast cancer and breast cancer cell lines prominently expressed PPAR $\gamma$ . In vitro, T inhibited the growth of PPAR $\gamma$ -positive MCF7 breast cancer cells and strongly upregulated lipid accumulation in these cells, but did not affect the normal breast epithelial cell line HB125. Furthermore, the combination of T with ATRA synergistically and irreversibly inhibited growth, as well as induced differentiation, apoptosis and down-regulated lipid accumulation in MCF7 cells. In vivo, T (100 mg/kg/day) significantly and non-toxicly inhibited MCF7 tumor growth in triple immunodeficient mice during 9 weeks of treatment. Combined treatment with T and ATRA (7.5 mg/kg/day) caused massive apoptosis, necrosis, and fibrosis in MCF7 tumors. Taken together, the combination of ligands for PPAR $\gamma$  and RAR inhibited growth and induced differentiation and apoptosis of breast cancer cells in vitro and in vivo; and therefore, it may provide a novel, non-toxic and selective therapy for human breast cancers.

**Submitted as an abstract to the Amer Assoc Cancer Res, 1997.**

## III. Molecular Biology of Breast Cancer

### III.1) Molecular analysis of INK4 genes in breast carcinomas

Authors: Spirin K, Simpson J, Miller CW, and Koeffler HP

Cell cycle regulators have recently been implicated in oncogenic transformation of cells, including the cyclins active in the G1 phase of the cell cycle and their respective cyclin-dependent kinases (CDK) whose activities are regulated by a set of inhibitors of CDK (CDKI). Since CDKIs can inhibit cell proliferation, they may have a role as tumor suppressor genes. To determine if alterations of CDKI genes may be involved in tumorigenesis of breast cancer, we examined the mutational status of p16<sup>INK4A</sup>, p15<sup>INK4B</sup>, p18<sup>INK4C</sup>, p19<sup>INK4D</sup> CDKI genes in 36 primary breast carcinomas and 9 breast cancer cell lines using polymerase chain reaction-single strand conformational polymorphism (PCR-SSCP), direct DNA sequencing, and Southern blot analysis. Furthermore, amplification of cyclin D1, D2, D3 genes were also examined in these samples. One mutation of p15<sup>INK4B</sup> gene occurred, resulting in change of aspartic acid to asparagine at codon 86. Since aspartic acid at this position is conserved between all four human and murine INK4 proteins, this missense mutation may have functional significance. The sample with a p15<sup>INK4B</sup> point mutation was accompanied by amplification of the cyclin D1 gene. A deletion

of the p18<sup>INK4C</sup> gene was found in a primary tumor. Three deletions of the p16<sup>INK4A</sup> gene and two deletions of the p15<sup>INK4B</sup> gene were found in the cell lines. Also, we found amplification of the p16<sup>INK4B</sup> and p16<sup>INK4A</sup> loci in a clinical sample as well as amplification of the p19<sup>INK4D</sup> in another sample, and amplification of the myeloperoxidase (MPO) gene in one cell line and two primary tumors. We suspect that a critical gene for breast cancer is amplified near the MPO gene. These data indicate that CDKI mutations are moderately rare in breast cancer and often associated with the simultaneous alteration of more than one cell-cycle regulatory gene.

**Int J Oncol, 11:737-744, 1997.**

III.2) **p 27KIP1 mutation found in breast cancer**

Authors: Spirin K, Simpson J, Takeuchi S, Kawamata N, Miller CW, and Koeffler HP.

The p27/Kip1 protein belongs to the recently identified family of proteins called cyclin-dependent kinase inhibitors. These proteins play an important role as negative regulators of cell cycle-dependent kinase activity during progression of the cell cycle. Since cyclin-dependent kinase inhibitors can inhibit cell proliferation, they may have a role as tumor suppressor genes. To determine whether p27 alterations may be involved in tumorigenesis, we examined its mutational status in 36 primary breast carcinomas and 9 breast cancer cell lines using PCR-single-strand conformational polymorphism, direct DNA sequencing, and Southern blot analysis. Southern blot analysis showed no homozygous deletions of the p27 gene in either the clinical samples or cell lines. Two point mutations were found in primary tumors. One represents a previously undescribed polymorphism at codon 142; another is a nonsense mutation at codon 104. The latter mutation was absent in the normal matched control sample, and, in addition, it was accompanied with the loss of heterozygosity (LOH) of a microsatellite marker in the vicinity of the p27 gene on chromosome 12p13. These data indicate that p27 mutations are a rare event in breast cancer, but may play an important role in the development of a minority of these cancers. Furthermore, LOH analysis of the 12p13 locus revealed that an additional four of six matched DNA samples had LOH at 12p13 but did not have an alteration of the p27 gene, suggesting that another tumor suppressor gene is located on the short arm of human chromosome 12 which may be frequently involved in the pathogenesis of breast cancers.

**Cancer Res 56:2400-2504, 1996**

## **CONCLUSION**

We have identified some particularly potent vitamin D analogs that inhibit the growth and induce differentiation of breast cancer cells. We have found that trogliterazone, a ligand for PPAR $\gamma$  synergizes with all-trans-retinoic acid in the inhibition of growth and induction of apoptosis of breast cancer cells. We have found that vitamin D analogs in combination with certain chemotherapeutic agents can enhance the effect of those chemotherapeutic agents, and finally; we have identified some of the molecular biology alterations of breast cancer.

## **REFERENCES**

Please see body of grant; references cited after each section.